Skip to main content
. 2021 Feb 26;60(13):7360–7365. doi: 10.1002/anie.202100583

Scheme 1.

Scheme 1

a) Marketed drugs containing 1,3‐substituted azetidine scaffolds. b) Electrophilic activation of ABB, nucleophilic addition to ABB and lithiation of ABB followed by reaction with boronic esters. c) Reaction of ABB‐Li with carbonyls and subsequent divergent reactivity.